http://www.ncbi.nlm.nih.gov/pubmed/24122953

Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology. 2014 May; 59(5):1964-71.
Abstract

Naim Alkhouri, Sana Mansoor, Paola Giammaria, Rocio Lopez, Valerio Nobili,
Gastroenterology 2014 May; 146 (7): s 40
http://www.gastrojournal.org/article/S0016-5085%2814%2960040-8/pdf

Background:

Noninvasive hepatic fibrosis scores that predict the presence of advanced fibrosis have been developed and validated in adult patients with NAFLD. There is an urgent need to test and develop similar scores in children with NAFLD. The aim of our study was to assess the utility of commonly used adult fibrosis scores in pediatric NAFLD and to develop a pediatric specific fibrosis score that can predict advanced fibrosis.

Methods:

http://www.ncbi.nlm.nih.gov/pubmed/24732866

Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014 May; 109(5):628-35.

Abstract

Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor Simeprevir (Olysio) and the nucleotide polymerase inhibitor Sofosbuvir (Sovaldi). The interferon-free regimen of Sofosbuvir and ribavirin is now available for genotype 2 and 3 patients. This regimen for 12 weeks is highly effective for genotype 2, whereas genotype 3 has proven to be more challenging and requires 24 weeks of therapy. Genotype 1 patients have reduced exposure to peginterferon-α with a 12-week regimen with sofosbuvir and a 24-week regimen with Simeprevir.